CoChat
Sign Up
Cited by 124Atrial Fibrillation Management and OutcomesVenous Thromboembolism Diagnosis and ManagementAcute Ischemic Stroke Management

The DOI matches its Crossref record; 14 of the 15 references it cites were found in a registry or an index.

SAMe-TT2R2 Score, Time in Therapeutic Range, and Outcomes in Anticoagulated Patients with Atrial Fibrillation

Open access
Gallego, Pilar, Roldán, Vanessa, Marin, Francisco, Gálvez, José, Valdés, Mariano, Vicente, Vicente, Lip, Gregory Y.H.·2014·The American Journal of Medicine
DOI 10.1016/j.amjmed.2014.05.023
Open this paper in CoChat — free account

Abstract

Background Oral anticoagulation is highly effective in preventing stroke and mortality in nonvalvular atrial fibrillation patients. However, the efficacy and safety of vitamin K antagonists (the main oral anticoagulation drug used) strongly depends upon the quantity of anticoagulation control, as reflected by the average percentage of the time in therapeutic range of international normalized ratio 2.0-3.0. An easy, simple prediction of which atrial fibrillation patients are likely to do well on vitamin K antagonists (with good average time in therapeutic range) could guide decision-making between using vitamin K antagonists (eg, warfarin) and non-vitamin K antagonist oral anticoagulants.Methods and results In a consecutive cohort of nonvalvular atrial fibrillation patients attending our anticoagulation clinic, we tested the hypothesis that the new Sex, Race, Medical history, Tobacco use, Race (SAMe-TT2R2) score was a predictor for good average time in therapeutic range, and second, this would translate into adverse events in a "real world" cohort of patients with nonvalvular atrial fibrillation. The incidence of bleeding, adverse cardiovascular events (including stroke/thromboembolism), and mortality during the follow-up was higher with increasing SAMe-TT2R2 score. The SAMe-TT2R2 score was predictive for the composite of all adverse events (hazard ratio 1.32 [95% Confidence Interval 1.17-1.50]; P <.001), adverse cardiovascular events (1.52 [1.28-1.83]; P <.001), and all-cause mortality (1.41 [1.16-1.67]; P = .001). A trend was also observed for major bleeding events (1.23 [0.99-1.53]; P = .059).Conclusion In a "real world" cohort of consecutive patients with nonvalvular atrial fibrillation, a high SAMe-TT2R2 score (reflecting poor anticoagulation control with poor time in therapeutic range) was associated with more bleeding, adverse cardiovascular events, and mortality during follow-up.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.amjmed.2014.05.023

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Citations

Cites

Cited by

Sorted by citations

See all 124

Related

See all

Metadata

Authors
Gallego, P., Roldán, V., Marin, F., Gálvez, J., Valdés, M., Vicente, V., & Lip, G. Y. H.
Affiliations
  • Birmingham City Hospital (GB)
  • Hospital General Universitario Morales Meseguer (ES)
  • Hospital Universitario Virgen de la Arrixaca (ES)
Corresponding author
Lip, Gregory Y.H.
ORCID
Venue
The American Journal of Medicine
Publisher
Elsevier BV
Published
2014-11
Volume
127
Issue
11
Pages
1083-1088
ISSN
0002-9343 (ISSN-L)
DOI
10.1016/j.amjmed.2014.05.023
OpenAlex
W2046171256
Cited by
124
References
15
Citations by year
2026: 1 · 2025: 1 · 2024: 2 · 2023: 4 · 2022: 3 · 2021: 5 · 2020: 6 · 2019: 6 · 2018: 14 · 2017: 17 · 2016: 30 · 2015: 32 · 2014: 3
FWCI
18.75
Type
journal article
Language
en
Open access
Licence
Locations
  • The American Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • University of Birmingham Research Portal (University of Birmingham) (submittedVersion, other-oa)
Funders
  • Spanish Foundation Alfonso Martín Escudero
  • Bayer
  • Bristol-Myers Squibb
  • Boehringer Ingelheim
  • Boston Scientifics
  • AstraZeneca
  • Daiichi-Sankyo
  • Astellas
  • Sanofi-Aventis
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
  • Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
  • Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
Keywords
non-valvular atrial fibrillation, oral anticoagulation, vitamin K antagonists, warfarin, SAMe-TT2R2 score, time in therapeutic range, international normalized ratio, anticoagulation management, bleeding risk, all-cause mortality, cardiovascular adverse events, risk prediction
MeSH terms
Aged, Aged, 80 and over, Anticoagulants, Atrial Fibrillation, Female, Follow-Up Studies, Hemorrhage, Humans, Male, Sex Factors, Thromboembolism, Vitamin K, Cohort Studies, Proportional Hazards Models, Risk Assessment, International Normalized Ratio, Stroke, Racial Groups, Tobacco Use

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review